BioVie to Present SUNRISE-PD Demographics from 60-Patient Parkinson’s Study
BioVie’s abstract from the SUNRISE-PD trial will be presented as a poster at the AD/PD 2026 conference in Copenhagen, showcasing demographics and baseline data from 60 early Parkinson’s patients treated with oral bezisterim. Topline efficacy and safety results from the Phase 2 SUNRISE-PD study are slated for mid-2026.
1. Conference Presentation Scheduled
BioVie has secured a poster slot at the AD/PD 2026 Advances in Science & Therapy meeting in Copenhagen, running March 17–21. The accepted abstract, titled “Demographics and Baseline Characteristics of Participants in a Study of Bezisterim (NE3107) in Early Parkinson’s Disease (SUNRISE-PD),” will outline initial trial population data.
2. SUNRISE-PD Study Details
The SUNRISE-PD trial enrolled 60 patients with early, untreated Parkinson’s disease to assess oral bezisterim’s impact on motor and non-motor symptoms without carbidopa/levodopa. The abstract focuses on participant age, disease duration, baseline motor scores and inflammatory marker profiles.
3. Topline Results Timeline and Pipeline Context
Topline efficacy and safety data from this Phase 2 study are expected in mid-2026, a key catalyst for valuation. Bezisterim also has active trials in long COVID and Alzheimer’s disease, and prior Phase 2 data showed improved motor control and minimal side effects in moderate-to-severe Parkinson’s patients.